Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
Moderna's stock has surged 696% year-to-date, driven by anticipation of its Phase 3 melanoma results for a personalized cancer therapy. The company's shares closed at $245.81, a 1.54% increase from the previous close. CEO comments on the company's mRNA technology and cancer vaccine have contributed to the stock's momentum.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Moderna's stock is up 696% within the year.
- ✓ Moderna's market cap is nearing $1 billion.
- ✓ The company's shares closed at $245.81, a 1.54% increase from the previous close.
What changed
Moderna's CEO discussed the company's focus on mRNA technology beyond Covid vaccines, specifically highlighting its cancer vaccine.
Live updates
-
Moderna Stock Hits New High as CEO Shifts Focus Beyond Covid Vaccines
Moderna's stock has surged 696% year-to-date, driven by anticipation of its Phase 3 melanoma results for a personalized cancer therapy. The company's shares closed at $245.81, a 1.54% increase from the previous close. CEO comments on the company's mRNA technology and cancer vaccine have contributed to the stock's momentum.
Why it matters
Moderna's growth is largely attributed to its potential in the cancer treatment market, with investors eagerly awaiting detailed Phase 3 results for its melanoma therapy. The company's return to the Nasdaq 100 and positive Phase III results for an mRNA cancer vaccine used with Keytruda have also fueled its stock surge.
What is confirmed
- Moderna's stock is up 696% within the year.
- Moderna's market cap is nearing $1 billion.
- The company's shares closed at $245.81, a 1.54% increase from the previous close.
Still unconfirmed
- CEO bought the stock at $29.
What to watch next
- Full Phase 3 data for intismeran at the ESMO meeting
- HR value, safety profile, and spillover effects of intismeran
confidence 90%Sources used for this update (4)
- www.gate.com — Moderna (MRNA) Rises 696% Year to Date: Can Phase 3 Cancer ...
- www.fool.com — Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
- www.fool.com — Breakfast News: A Conversation With Moderna’s CEO
- finance.yahoo.com — Moderna (MRNA) Rises Higher Than Market: Key Facts
-
Moderna Stock Hits New High on Cancer Vaccine Data
Moderna's stock has surged 4.4% and is up over 600% this year, driven by anticipation of detailed Phase 3 melanoma results for a personalized cancer therapy. The company's shares jumped after previous momentum from Phase III results for an mRNA cancer vaccine used with Keytruda and its return to the Nasdaq 100.
Why it matters
Moderna is best known for its COVID vaccines, but the company is expanding its portfolio. The surge in stock price reflects investors' hopes for growth beyond COVID-19 products. Moderna's mRNA technology has shown promise in treating various cancers.
What is confirmed
- Moderna stock is up over 600% this year
- Moderna stock hit a new 52-week high of $243.00
- The company's shares jumped 7% as the market positions for a data presentation
- Moderna spent much of 2025 caught between bullish hopes for mRNA expansion and bearish warnings about shrinking COVID demand and tighter pricing
- For Moderna shareholders, the return over the past year was 671.9%, including dividends
Still unconfirmed
- The company's mRNA vaccine was approved at remarkable speed at the peak of the COVID-19 pandemic
What to watch next
- Detailed Phase 3 melanoma results for a personalized cancer therapy presentation in Madrid
- Future developments in mRNA technology for cancer treatment
confidence 80%Sources used for this update (4)
- pomegra.io — Moderna Stock Rises 4.4% as ESMO Cancer Vaccine Data Nears
- www.abcmoney.co.uk — Moderna Stock Is Up 600% This Year — But the Real Story Is ...
- finance.yahoo.com — After Moderna's 672% Climb, The Story Has Changed
- www.quiverquant.com — Why Moderna (MRNA) Stock Is Up Today | Quiver Quantitative
-
Moderna Shares Reach 52-Week High Ahead of Cancer Data Presentation
Moderna stock hit a new 52-week high of $243.00 on Tuesday, closing at $237.8580. Investors are driving the price increase in anticipation of detailed Phase 3 melanoma results for a personalized cancer therapy. The company's shares jumped 7% as the market positions for a data presentation scheduled for Saturday in Madrid. This surge follows previous momentum from Phase III results for an mRNA cancer vaccine used with Keytruda and the company's return to the Nasdaq 100.
Why it matters
The company is attempting to diversify its portfolio beyond Covid vaccines by expanding its oncology pipeline. High price-to-sales ratios and significant losses have led some analysts to warn that current valuations may already account for future successes.
What is confirmed
- Moderna shares reached a 52-week high of $243.00 on Tuesday.
- Moderna stock closed at $237.8580 on Tuesday with a volume of 11,413,108 shares.
- The stock previously closed at $226.89.
Still unconfirmed
- Positive melanoma data presented Saturday could strengthen the oncology pipeline and support a broader re-rating.
What to watch next
- The Phase 3 melanoma results presentation in Madrid this Saturday.
confidence 100%Sources used for this update (2)
- finance.yahoo.com — Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol ...
- www.marketbeat.com — Moderna (NASDAQ:MRNA) Sets New 1-Year High - MarketBeat
-
Moderna Shares Surge Over 600% Amid Cancer Vaccine Progress
Moderna stock has risen more than 650% year-to-date, reaching new 52-week highs driven by positive Phase III results for an mRNA cancer vaccine used with Keytruda. Investors are reacting to the company's role in a national cancer combat effort and its return to the Nasdaq 100. While momentum remains high, some analysts warn that current valuations may already price in future success due to significant losses and a high price-to-sales ratio. Goldman Sachs recently increased its price target to $137, though it maintains a Neutral rating.
Why it matters
The shift toward oncology marks Moderna's effort to diversify beyond its primary revenue source of Covid-19 vaccines. This transition relies on the scalability of the mRNA platform for personalized medicine. Market volatility persists as institutional optimism clashes with fundamental valuation concerns.
What is confirmed
- Moderna stock has surged more than 650% year-to-date.
- Positive Phase III results for an mRNA cancer vaccine combined with Keytruda have influenced the company's oncology narrative.
- Moderna stock reached new 52-week highs.
- The company is involved in a national effort to combat cancer.
Still unconfirmed
- Goldman Sachs analyst Salveen Richter raised the price target on Moderna to $137 from $120.
What to watch next
- The release of full cancer vaccine data at the ESMO annual meeting.
- Further analyst adjustments to price targets relative to the current share price.
confidence 90%Sources used for this update (6)
- www.timothysykes.com — MRNA Stock Surges On Cancer Vaccine Catalysts And Nasdaq-100 Move
- finance.yahoo.com — Moderna stock surges more than 600% in 2026 - Yahoo Finance
- finance.yahoo.com — Why Moderna Stock Surged Today - Yahoo Finance
- finance.yahoo.com — Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too ...
- longbridge.com — Amid the "Cancer Vaccine" Fever, Moderna's Stock Hits New ...
- stocktwits.com — MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target ...
-
Moderna Shares Jump 14 Percent to Hit New 52-Week High
Moderna stock surged 14.21 percent to reach a new 52-week peak. The market rally was driven by the company returning to the Nasdaq 100 index, institutional re-entry, and ongoing clinical momentum in personalized cancer vaccines. Additional momentum came from reports detailing a planned national initiative by the National Institutes of Health to accelerate cancer vaccine development. Investors also responded to positive mRNA pipeline data and a price target increase. Meanwhile, a recent Bank of America downgrade raised questions about valuation, tempering some of the widespread market optimism surrounding the stock.
Why it matters
The recent stock surge marks a significant milestone for Moderna as it seeks to demonstrate value beyond its traditional Covid-19 vaccines. Inclusion in the Nasdaq 100 index brings renewed institutional attention and capital flows. Clinical progress in personalized cancer treatments has helped reposition the biotechnology firm in the eyes of investors.
What is confirmed
- Moderna shares surged 14.21 percent to reach a new 52-week high.
- The stock rally was driven by the company returning to the Nasdaq 100 index and clinical momentum in personalized cancer vaccines.
What to watch next
- Developments regarding the National Institutes of Health cancer vaccine initiative
- Future updates on the Moderna mRNA pipeline and clinical data
confidence 100%Sources used for this update (3)
- www.thecorequant.com — Why Moderna (NASDAQ:MRNA) Stock Jumped 14% to a 52-Week High ...
- www.top1markets.com — Moderna (MRNA) Stock Hits 52-Week New High: Here Is Why
- www.archyde.com — Moderna Shares Surge on Nasdaq 100 Return and ... - Archyde
-
Moderna Shares Hit Multi-Year High on Cancer Vaccine Effort
Moderna shares surged 9 percent on Friday, reaching a four-year high and setting a new 52-week peak. The stock climbed as investors reacted to a New York Times report detailing a planned national initiative by the National Institutes of Health to accelerate cancer vaccine development. Additional market momentum stemmed from the company joining the Nasdaq-100 index, positive mRNA pipeline data, and an increased price target. Despite the strong rally and widespread investor optimism, a Bank of America downgrade introduced fresh valuation questions regarding the stock.
Why it matters
The recent market surge positions Moderna beyond its traditional reliance on Covid-19 vaccines by highlighting its broader therapeutic pipeline, particularly in oncology. This upward trajectory included joining the Nasdaq-100 index and benefiting from broader market movements that pushed the S&P 500 near record highs. Analysts and market observers continue to debate whether the soaring valuation is sustainable following the rapid share price expansion.
What is confirmed
- Moderna shares jumped 9 percent on Friday to hit a four-year high.
- The New York Times reported on a planned NIH-backed national effort to speed up cancer vaccine development.
- Moderna stock rose following its entry into the Nasdaq-100 index and positive mRNA pipeline data.
- A Bank of America downgrade raised fresh valuation questions for Moderna stock.
Still unconfirmed
- Moderna will specifically capture the majority of the benefits from the planned national cancer vaccine effort.
What to watch next
- Official announcements and structural details regarding the NIH-backed national cancer vaccine initiative
- Subsequent analyst price target revisions and valuation assessments following the stock surge
- Performance and adoption data from Moderna's broader mRNA pipeline and skin cancer combination therapies
confidence 95%Sources used for this update (6)
- stockminded.com — Moderna Stock Has Exploded Higher in 2026 – Is the Rally ...
- stockstotrade.com — MRNA Jumps As Nasdaq-100 Inclusion And Cancer Pipeline Shift Momentum
- www.timothysykes.com — MRNA Stock Jumps As Nasdaq-100 Inclusion Ignites Momentum
- finance.yahoo.com — MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push
- finance.yahoo.com — Moderna stock hits 4-year high on planned national cancer vaccine effort
- pro.thestreet.com — A Broad Friday Rally Takes the S&P 500 Just Below Record Highs
-
Moderna Stock Rises on Cancer Vaccine Pipeline and Nasdaq 100 Entry
Moderna shares hit a 12-month high of $208.90 as investors react to growth prospects for a skin cancer combined therapy candidate. The stock climbed nearly 600% this year and ranked as the second top-performing US stock in the third quarter, rising 175% during that period. This momentum comes as the company prepares to replace Warner Bros. Discovery in the Nasdaq 100 index on October 9. While the company's Q1 revenues reached $389m, market analysts remain divided on whether the current valuation is overpriced.
Why it matters
The shift in valuation reflects a transition from Covid-19 vaccine reliance to a diversified oncology pipeline. The company is specifically targeting the most common type of skin cancer. This pivot occurs while broader market averages face pressure from rising yields.
What is confirmed
- Moderna will replace Warner Bros. Discovery in the Nasdaq 100 index on October 9.
- Moderna shares reached a 12-month high of $208.90 on a volume of 2574237 shares.
- The stock was the second top-performing US stock in the third quarter, increasing 175%.
Still unconfirmed
- Moderna stock has surged nearly 600% this year.
- Q1 sales rose to $389m, nearly tripling compared to the same period in 2025.
- The stock surge is linked to a melanoma readout that has not been seen in full by most outside the trial.
What to watch next
- The release of complete melanoma trial data to the market.
- The official index transition on October 9.
confidence 90%Sources used for this update (5)
- www.marketbeat.com — MRNA News Today | Why did Moderna stock go up today? - MarketBeat
- 247wallst.com — Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
- finance.yahoo.com — MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail ...
- finance.yahoo.com — Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?
- pharmaphorum.com — Moderna's Q1 revenues rocket, thanks to ex-US sales
-
Moderna Hits New High as Nasdaq 100 Addition Nears
Moderna shares reached a new 12-month high of $208.90 on a trading volume of 2574237 shares amid a major surge fueled by enthusiasm over its cancer vaccine pipeline. Nasdaq announced that the biotechnology company will replace Warner Bros. Discovery on the Nasdaq 100 index starting October 9. While the stock climbs and draws positive analyst attention, market commentators debate whether the soaring valuation is overpriced. Broader major market averages are heading toward a losing week as rising yields pressure equities.
Why it matters
Moderna is based in Cambridge, Massachusetts, and focuses primarily on RNA therapeutics and messenger RNA vaccines that carry instructions for proteins to produce an immune response. The company develops products such as the mNEXSPIKE COVID-19 vaccine for people 65 and older or ages 12 to 64 at high risk. Alongside infectious disease work, a personalized mRNA cancer vaccine combined with Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma.
What is confirmed
- Moderna shares climbed to a new 12-month high of $208.90 on trading volume of 2574237 shares.
- Nasdaq announced that Moderna will replace Warner Bros. Discovery on the Nasdaq 100 index starting October 9.
- A personalized mRNA cancer vaccine combined with Keytruda succeeded in a late-stage trial for melanoma.
- The combination regimen significantly extended the time patients lived without their melanoma returning compared with Keytruda alone.
Still unconfirmed
- Market commentators debate whether Moderna's soaring valuation is overpriced.
What to watch next
- The official Nasdaq 100 index inclusion date of October 9, 2026.
- Broader market movements and Treasury yield pressures affecting equity valuations.
confidence 100%Sources used for this update (12)
- www.modernatx.com — Pioneering mRNA technology - Moderna
- www.modernatx.com — Company Culture - Moderna
- finance.yahoo.com — Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo...
- www.cnn.com — Moderna and Merck say melanoma vaccine succeeded in large trial
- www.cnbc.com — Moderna, Merck cancer vaccine shows initial late-stage melanoma...
- news.modernatx.com — Press Releases - Moderna
- products.modernatx.com — mNEXSPIKE® (COVID-19 Vaccine, mRNA) by Moderna
- labels.modernatx.com — Moderna
- en.wikipedia.org — Moderna - Wikipedia
- products.modernatx.com — Find vaccines by Moderna near you
- economictimes.indiatimes.com — Sputnik V Vaccine
- www.devdiscourse.com — Reuters Health News Summary
-
Moderna Stock Hits New High and Joins Nasdaq 100
Moderna shares climbed to a new 12-month high of $208.90 on trading volume of 2574237 shares, building on a massive 2026 surge driven by cancer vaccine enthusiasm. Nasdaq announced that the vaccine maker will replace Warner Bros. Discovery on the Nasdaq 100 index starting October 9. While the stock hits fresh peaks and catches positive analyst attention, market commentators debate whether the soaring valuation is overpriced. Broader major market averages are heading toward a losing week as rising yields pressure equities.
Why it matters
The vaccine maker is expanding beyond its core Covid-19 products through its mRNA technology platform, notably developing a melanoma recurrence vaccine that has fueled investor optimism. Financial institutions have adjusted their outlooks on the company, including William Blair initiating coverage with an outperform rating and Bank of America upgrading the stock to neutral.
What is confirmed
- Moderna shares reached a new 52-month high of $208.90 with a trading volume of 2574237 shares.
- Nasdaq will replace Warner Bros. Discovery with Moderna on the Nasdaq 100 index effective October 9.
- Bank of America previously upgraded Moderna from an underperform rating to a neutral rating on August 19.
- William Blair initiated coverage on Moderna with an outperform rating on August 28.
Still unconfirmed
- Major averages are heading for a losing week because rising yields keep stocks under pressure.
What to watch next
- The effective date of October 9 for Moderna joining the Nasdaq 100 index.
- Future trial results and commercial updates for Moderna's therapeutic cancer vaccines and mRNA pipeline.
- Analyst rating changes and stock performance amidst broader market yield pressures.
confidence 95%Sources used for this update (4)
- www.cnbc.com — Stock market today: Live updates - CNBC
- www.devdiscourse.com — Reuters Health News Summary
- www.marketbeat.com — Moderna (NASDAQ:MRNA) Sets New 12-Month High - Here's What ...
- bobby.ai — Moderna's 550% Surge: Is MRNA Still a Buy? | Bobby
-
Moderna Stock Hits 52-Week High on Cancer Vaccine and Platform Shift
Moderna shares surged to a fresh 52-week high of $195.71, capping a two-month rally driven by optimism surrounding the company's therapeutic cancer vaccine and its broader mRNA technology platform. The stock climbed from $63 following positive trial results for a melanoma recurrence vaccine and encouraging statements from CEO Bancel regarding commercial applications outside of Covid-19 vaccines. Investors rewarded drug development companies amid improving market sentiment and analyst commentary highlighting the expanding mRNA cancer pipeline.
Why it matters
The company relies heavily on transitioning from its pandemic-era Covid-19 vaccine revenue toward diversified healthcare products. Progress in cancer immunotherapy creates a pathway for long-term growth and shifts market perception of the platform's value. Broader market interest in drug development alongside artificial intelligence also supported equity gains last week.
What is confirmed
- Moderna stock hit a fresh 52-week high of $195.71 on Thursday.
- Shares rose from around $63 beginning August 18.
- CEO Bancel stated the company is an mRNA platform, not just a Covid vaccine maker.
- Moderna reported trial results for a therapeutic cancer vaccine aimed at preventing melanoma recurrence on September 25, 2026.
What to watch next
- Further clinical trial data on the therapeutic cancer vaccine for melanoma recurrence
- Analyst updates regarding Moderna's transition away from Covid-19 vaccine reliance
- S&P 500 performance rankings for September
confidence 100%Sources used for this update (8)
- coincentral.com — Moderna (MRNA) Stock Hits 52-Week High on Cancer Vaccine ...
- finance.yahoo.com — Why Did AMD, HPE, MRNA Stocks Surge To 52-Week Highs Last Week?
- finance.yahoo.com — From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
- guavy.com — Moderna Stock Soars to Fresh High as CEO Sees Beyond Covid
- finance.yahoo.com — Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today?
- www.gate.com — Moderna Stocks Hit $195 52-Week High After Cancer Vaccine ...
- finance.yahoo.com — MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The ...
- www.gurufocus.com — Moderna's Cancer Vaccine Boosts Stock Amid CEO Insights
-
Moderna Stock Reaches New High as Company Expands Beyond Covid Vaccines
Moderna stock has hit a new high as the company shifts its focus toward a broader portfolio of mRNA applications. The company is currently on track to be the second best performing S&P 500 stock for September. This growth follows statements from the CEO regarding the company's innovation strategy and the development of cancer vaccines. While the stock trends positively, the company is working to transition from its primary reliance on Covid-19 vaccines to a more diversified healthcare provider.
Why it matters
Moderna gained global prominence through its rapid development of mRNA Covid-19 vaccines. The current shift toward personalized cancer treatments represents a strategic move to ensure long-term viability as pandemic-era demand declines. This transition depends on the success of clinical tests for new mRNA applications.
Still unconfirmed
- The CEO describes Moderna as being more than just a provider of Covid vaccines.
- Moderna is developing a personalized mRNA cancer vaccine that recently passed a major test.
- Moderna is on track to be the No. 2 S&P 500 stock for September.
What to watch next
- Clinical trial results for the personalized mRNA cancer vaccine.
- Quarterly earnings reports detailing revenue diversification away from Covid vaccines.
confidence 70%Sources used for this update (7)
- economictimes.indiatimes.com — Moderna Vaccine
- Barron's — Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
- Yahoo Finance — MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
- WSJ — Moderna CEO’s Realistic Approach to Innovation
- Trefis — Was Moderna Stock’s Cancer Vaccine Run Visible In Advance?
- Medical Daily — Opinion: The First Personalized mRNA Cancer Vaccine Just Passed a Major Test: Now Comes the Hard Part
- Benzinga — Moderna Stock Trends After Hours - Moderna (NASDAQ:MRNA), Merck & Co (NYSE:MRK)
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community